An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels

Br J Haematol. 2013 Apr;161(2):282-6. doi: 10.1111/bjh.12209. Epub 2013 Jan 7.

Authors

Thies Rösner¹, Stefanie Derer, Christian Kellner, Michael Dechant, Stefan Lohse, Gestur Vidarsson, Matthias Peipp, Thomas Valerius

Affiliation

¹ Division of Stem Cell Transplantation and Immunotherapy, 2nd Department of Medicine, Christian-Albrechts-University and University Hospital Schleswig-Holstein, Kiel, Germany.

PMID: 23294176
DOI: 10.1111/bjh.12209

No abstract available

Publication types

Letter

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Murine-Derived / immunology*
Antibodies, Monoclonal, Murine-Derived / therapeutic use
Antigens, CD20 / blood
Antigens, CD20 / immunology*
Antineoplastic Agents / immunology*
Antineoplastic Agents / therapeutic use
Complement Pathway, Classical*
Complement System Proteins / immunology*
Complement System Proteins / metabolism
Dose-Response Relationship, Immunologic
Female
Gene Expression Regulation, Leukemic / immunology
Humans
Immunoglobulin G / immunology*
Immunoglobulin G / therapeutic use
Leukemia, Lymphocytic, Chronic, B-Cell / blood
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell / immunology*
Male
Middle Aged
Rituximab

Substances

Antibodies, Monoclonal, Murine-Derived
Antigens, CD20
Antineoplastic Agents
Immunoglobulin G
Rituximab
Complement System Proteins